Summary
No specific treatment of the schizophrenias and other psychoses was available until Laborit’s discovery of chlorpromazine as the first antipsychotic agent. Since then the introduction of widespread use of antipsychotic drugs has led to a marked reduction in the number of hospitalised shizophrenic patients. Hundreds of controlled studies have demonstrated the superiority of antipsychotic drugs over placebo in the treatment of schizophrenia.
Different classes of antipsychotic drugs are equally effective in the treatment of psychoses when administered in adequate doses, but they differ in range and severity of side-effects. For the average schizophrenic patient, mega doses of antipsychotic drugs do not produce greater improvement than conventional doses. The same dose of antipsychotic drugs leads to widely divergent drug blood levels in individual patients, due to differences in absorption, and rate of elimination of the drug.
Maintenance treatment with antipsychotic drugs reduces the relapse rate in schizophrenic patients.
Side-effects of antipsychotic drugs involve the autonomic nervous system and the cardiovascular system, as well as the CNS with the development of extrapyramidal symptoms; in addition skin and eye changes, as well as allergic and endocrine changes, occur. Late or tardive dyskinesia is an extrapyramidal syndrome which can occur after long-term antipsychotic treatment and may be reversible when recognised in the initial stages.
Similar content being viewed by others
References
Adelson, D. and Epstein, L.A.: A study of phenothiazines in male and female chronically ill schizophrenics. Journal of Nervous and Mental Diseases 134: 543–554 (1962).
Baro, F.; Brugmans, J.; Dom, R. et al.: Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. Journal of Clinical Pharmacology 10: 330–341 (1970).
Bishop, M.P. and Gallant, D.M.: Loxapine: A controlled evaluation in chronic schizophrenic patients. Current Therapeutic Research 12: 594–597 (1970).
Blackburn, J. and Allen, J.: Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. Journal of Nervous and Mental Diseases 133: 303–307(1961).
Caffey, E.M.; Diamond, L.S.; Frank, T.V. et al.: Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 17: 347–358 (1964).
Casey, J.F.; Hollister, L.E.; Klett, C.J.; Lasky, J.J. and Cafey, E.M.: Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 117: 997–1003(1961).
Charalampous, K.D.; Freemesser, G.F.; Maley, J. et al.: Loxapine succinate: a controlled double blind study in schizophrenia. Current Therapeutic Research 16: 829–837 (1974).
Clark, M.; Huber, W.K.; Sakata, K. et al.: Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 11: 680–688(1970).
Clark, M.L.; Huber, W.K.; Sullivan, J. et al.: Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 33: 783–791 (1972).
Clark, M.L.; Parades, A.; Costiloe, J.P. et al.: Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology 15: 286–294(1975).
Clark, M.L.; Ramsey, R.; Rahhal, D.K., et al.: Chlorpromazine in chronic schizophrenia: The effect of age and hospitalisation in behavioral dose-response relationships. Archives of General Psychiatry 27: 479–483(1972).
Cole, J.O.; Goldberg, S.C. and Klerman, G.L.: Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10: 246–261 (1964).
Cooper, T.B. and Simpson, G.M.: Plasma/blood level monitoring techniques in psychiatry; in Gottschalk and Merlis (Eds) Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response (Spectrum, New York 1976).
Curry, S.H.; Davis, J.M.; Janowsky, D.S. et al.: Factors affecting chlorpromazine plasma levels in psychiatric patients. Archives of General Psychiatry 22: 209–215 (1970a).
Curry, S.H. and Marshall, J.H.L.: Plasma levels of chlorpromazine and some of its relatively nonpolar metabolites in psychiatric patients. Life Science 7: 9–17 (1968).
Curry, S.H.; Marshall, J.H.L.; Davis, J.M. et al.: Chlorpromazine plasma levels and effects. Archives of General Psychiatry 22: 289–296 (1970b).
Davis, J.M.: Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research 11: 65–69 (1974).
Davis, J.M.: Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 33: 858–861 (1976).
Denber, H.: Oxilapine vs trifluoperazine. Psychopharmacology Bulletin 6: 93–94(1970).
De Silva, L. and Huang, C.Y.: Deanol in tardive dyskinesia. British Medical Journal 3: 466–467 (1975).
De Wied, D. and Jong, W.: Drug effects and hypothalamic anterior pituitary function. Annual Review of Pharmacology 14: 389–412(1974).
Diamond, L.S. and Marks, J.B.: Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage. Journal of Nervous and Mental Diseases 131: 247–251 (1960).
Engelhardt, D.M.; Rosen, B.; Freedman, D. et al.: Phenothiazines in the prevention of psychiatric hospitalisation. Archives of General Psychiatry 16: 98–99 (1967).
Ericksen, S.E.; Haraszti, J.S.; Dekirmenjian, H. and Davis, J.M.: Loading dose versus standard dose haloperidol in decompensated schizophrenic patients: a double blind study. Submitted to the American Journal of Psychiatry (1977).
Filho, V.V.; Caldeira, M.V.N. and Bueno, J.R.: The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study. Current Therapeutic Research 18: 476–490(1975).
Freeman, H. and Frederick, A.N.: Comparison of trifluoperazine and molindone in chronic schizophrenic patients. Current Therapeutic Research 11: 670–676 (1969).
Freeman, L.S. and Alson, E.: Prolonged withdrawal of chlorpromazine in chronic patients. Diseases of the Nervous System 23: 522–525(1962).
Gallant, D.M. and Bishop, M.P.: Molindone: controlled evaluation in chronic schizophrenic patients. Current Therapeutic Research 10: 441–447 (1968).
Gardos, G. and Cole, J.O.: Papaverine for tardive dyskinesia. New England Journal of Medicine 292: 355 (1975).
Garver, D.L.; Davis, J.M.; Dekirmenjian, H.; Jones, F.D.; Casper, R. and Haraszti, J.: Pharmacokinetics of red blood cell phenothiazine and clinical effects. Archives of General Psychiatry 33: 862–866(1976).
Garfield, S.; Gershon, S.; Sletten, L. et al.: Withdrawal of ataractic medication in schizophrenic patients. Diseases of the Nervous System 27: 321–325 (1966).
Good, W.W.; Sterling, M. and Holtzman, W.H.: Termination of chlorpromazine with schizophrenic patients. American Journal of Psychiatry 115: 443–448 (1958).
Greenblatt, M.; Solomon, M.H.; Evans, A.S. and Brooks, G.W. (Eds): Drug and Social Therapy in Chronic Schizophrenia (Thomas, Springfield Ill. 1965).
Grinspoon, L.; Ewalt, J.R. and Shader, R.I.: Schizophrenia, Pharmacotherapy and Psychotherapy (Williams and Wilkins, Baltimore 1972).
Gross, M. and Reeves, W.P. Relapse after withdrawal of ataractic drugs in mental patients in transition; in Greenblatt (Ed), pp.313–321 (Thomas, Springfield Ill. 1961).
Goldberg, S.C.; Klerman, G.L. and Cole, J.O.: Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry III: 120–133(1965).
Hanlon, T.E.; Nussbaum, K., Wittig, B.; Hanlon, D.D. and Kurland, A.A.: The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients. Journal of New Drugs 4: 52–60(1964).
Hershon, H.I.; Kennedy, P.F. and McGuire, R.J.: Persistence of extrapyramidal disorders and psychiatric relapse after with-drawal of long-term phenothiazine therapy. British Journal of Psychiatry 120: 41–50(1972).
Hirsch, S.R.; Gaind, R.; Rohde, P.D. et al.: Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine double blind placebo trial. British Medical Journal 1: 633–637(1973).
Hogarty, G.E. and Goldberg, S.C.: Drugs and sociotherapy in the aftercare of schizophrenic patients. One year relapse rates. Archives of General Psychiatry 28: 54–62 (1973).
Hogarty, G.E.; Goldberg, S.C.; Schooler, N.R. et al.: Drugs and sociotherapy in the aftercare of schizophrenic patients. Archives of General Psychiatry 31: 603–618 (1974).
Hollister, L.E.; Overall, J.E.; Meyer, F. and Shelton, J.: Perphenazine combined with amitriptyline in newly admitted schizophrenics. American Journal of Psychiatry 120: 591–592 (1963).
Itil, I.M.; Polvan, N.; Ucok, A. et al.: Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Physicians Drug Manual 2: 80–87 (1970).
Janowsky, D.S.; Sekerke, H.J.; Davis, J.M.; Morris, D.R.; El-Yousef, M.K. and Decker, B.: Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism. New England Journal of Medicine 286: 785 (1972).
Klein, D.F. and Davis, J.M.: Diagnosis and Drug Treatment of Psychiatric Disorders (Williams and Wilkins, Baltimore 1969).
Leff, J.P. and Wing, J.K.: Trial of maintenance therapy in schizophrenics. British Medical Journal 2: 599–604 (1971).
Marjerrison, G.; Irvine, D.; Stewart, C.N. et al.: Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal 9: 290–298(1964).
Maxwell, J.D. and Curry, S.H.: Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clinical Science 43: 142(1972).
May, P.R.: Treatment of Schizophrenia (Science House, New York 1968).
May, P.R.A.; Tuma, A.H. and Dixon, W.J.: Schizophrenia— A followup study of results of treatment I. Design and other problems. Archives of General Psychiatry 33: 474–478 (1976a).
May, P.R.A.; Tuma, A.H.; Yale, C; Potepan, P. and Dixon, W.J.: Schizophrenia — A followup study of results of treatment II. Hospital stay over two to five years. Archives of General Psychiatry 33: 481–486 (1976b).
Melynk, W.T.; Worthington, A.G. and Laverty, S.G.: Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients. Canadian Psychiatric Association Journal 11: 410–413 (1966).
Michaux, M.H.; Kurland, A.A. and Agallianos, D.: Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research 8(Suppl.): 117–152 (1966).
Miller, E.: Deanol: A solution for tardive dyskinesia. New England Journal of Medicine 291: 796–797 (1974).
Moore, D.F.: Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine. Current Therapeutic Research 1 8: 172–180 (1975).
Morton, M.R.: A study of withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry 124: 1585–1588(1968).
Moyano, Zarata, C. A double-bind comparison of loxitane loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Diseases of the Nervous System 36: 301–304(1975).
National Institute of Mental Health Psychopharmacology Research Branch Collaborative Study Group: Short-term improvement in schizophrenia: the contribution of background factors. American Journal of Psychiatry 124: 900–909 (1968).
Prien, R.F. and Cole, J.O.: High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health. Psychopharmacology Research Branch Collaborative Study Group. Archives of General Psychiatry 18: 482–495 (1968).
Prien, R.F.; Levine, J. and Cole, J.O.: High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry 126: 305–313(1969).
Prien, R.F.; Levine, J. and Switalski, R.W.: Discontinuation of chemotherapy for chronic schizophrenics: results from two collaborative studies. Hospital Community Psychiatry 22: 4–7 (1971).
Quitkin, R.; Rifkin, A. and Klein, D.F.: Very high dose vs standard dosage fluphenazine in schizophrenia. Archives of General Psychiatry 32: 1276–1281 (1975).
Ramsay, R.A.; Ban, T.A.; Lehmann, H.E. et al.: A comparative study of molindone and trifluoperazine. Current Therapeutic Research 12: 438–449(1970).
Rassidakis, N.C.; Kondakis, X.; Papanastassiou, A. et al.: Withdrawal of antipsychotic drugs from chronic patients. Bulletin. Menninger Clinic 34: 216–222 (1970).
Re, O.N.: Deanol in L-Dopa and tardive dyskinesia: A Review. Current Therapeutic Research 18: 872–874(1975).
Schawver, J.; Gorham, D.R.; Leskin, L.W. et al.: Comparison of chlorpromazine and reserpine in maintenance drug therapy. Diseases of the Nervous System 20: 452–457 (1959).
Schiele, B.C.: Loxapine succinate: A controlled double-blind study in chronic schizophrenia. Diseases of the Nervous System 18: 361–364(1975).
Schiele, B.C.; Vestre, N.D. and Stein, K.E.: A comparison of thioridazine, trifluoperazine, chlorpromazine and placebo: A double blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical Experimental Psychopathology 22: 151–162 (1961).
Shopsin, B.; Pearson, E.; Gershon, S. et al.: A controlled double blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients. Current Therapeutic Research 14: 739–748 (1972).
Simpson, G.M.; Amin, M. and Edwards, J.G.: A double blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia. Journal of Clinical Pharmacology 11: 227–236 (1971).
Simpson, G.M. and Cuculic, Z.: A double blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. Journal of Clinical Pharmacology (in press).
Steinbook, R.M.; Goldstein, B.J.; Brauzer, B. et al.: Loxapine: A double blind comparison with chlorpromazine in acute schizophrenic patients. Current Therapeutic Research 15: 1–7 (1973).
Tamminga, C.A.; Smith, R.C.; Ericksen, S.E.; Chang, S. and Davis, J.M.: Cholinergic influences in tardive dyskinesia. American Journal of Psychiatry 1 34: 769–774 (1977).
Troshinsky, C.H.; Aaronson, H.G. and Stone, R.K.: Maintenance phenothiazine in the aftercare of schizophrenic patients. Pennsylvania Psychiatric Quarterly 2: 11–15 (1962).
Van der Velde, CD. and Kiltie, H.: Effectiveness of loxapine suc-cinate in acute schizophrenia: A comparative study with thiothixene. Current Therapeutic Research 17: 1–12 (1975).
Whitaker, C.B. and Hoy, R.M.: Withdrawal of perphenazine in chronic schizophrenia. British Journal of Psychiatry 109: 422–427(1963).
Wijsenbeek, H.; Steiner, M. and Goldberg, S.C.: Trifluoperazine: A comparison between regular and high doses. Psychophar-macologia 36: 147–150(1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, J.M., Casper, R. Antipsychotic Drugs: Clinical Pharmacology and Therapeutic Use. Drugs 14, 260–282 (1977). https://doi.org/10.2165/00003495-197714040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197714040-00002